Immunocore Holdings PLC (6YGy)

Currency in EUR
28.00
-0.20(-0.71%)
Delayed Data·
6YGy is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.0028.00
52 wk Range
23.0034.80
Key Statistics
Bid/Ask
27.80 / 28.00
Prev. Close
28.2
Open
28
Day's Range
28-28
52 wk Range
23-34.8
Volume
10
Average Volume (3m)
395
1-Year Change
-22.95%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6YGy Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Immunocore Holdings PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Immunocore Holdings PLC Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Compare 6YGy to Peers and Sector

Metrics to compare
6YGy
Peers
Sector
Relationship
P/E Ratio
0.0x−1.9x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.0x1.2x2.6x
Price / LTM Sales
0.0x4.8x3.3x
Upside (Analyst Target)
0.0%252.9%43.5%
Fair Value Upside
Unlock32.4%6.3%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

6YGy Income Statement

People Also Watch

114.70
CRDO
+6.64%
36.81
EXEL
-1.21%
153.81
SFM
-0.18%
52.25
PTCT
+0.23%
102.60
ENVA
+2.03%

FAQ

What Stock Exchange Does Immunocore Holdings PLC Trade On?

Immunocore Holdings PLC is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Immunocore Holdings PLC?

The stock symbol for Immunocore Holdings PLC is "6YGy."

What Is the Immunocore Holdings PLC Market Cap?

As of today, Immunocore Holdings PLC market cap is 1.41B.

What Is Immunocore Holdings PLC's Earnings Per Share (TTM)?

The Immunocore Holdings PLC EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 6YGy a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Immunocore Holdings PLC Stock Split?

Immunocore Holdings PLC has split 0 times.

What is the current trading status of Immunocore Holdings PLC (6YGy)?

As of 05 Aug 2025, Immunocore Holdings PLC (6YGy) is trading at a price of 28.00, with a previous close of 28.20. The stock has fluctuated within a day range of 28.00 to 28.00, while its 52-week range spans from 23.00 to 34.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.